<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR8">
 <label>8.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Akihisa</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Kawauchi-Miki</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Miki</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Sato</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Wakasa-Morimoto</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Fujiwara</surname>
    <given-names>T</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro</article-title>
  <source>Antimicrob Agents Chemother.</source>
  <year>2015</year>
  <volume>59</volume>
  <issue>5</issue>
  <fpage>2596</fpage>
  <lpage>2606</lpage>
  <pub-id pub-id-type="doi">10.1128/AAC.04844-14</pub-id>
  <pub-id pub-id-type="pmid">25691633</pub-id>
 </element-citation>
</ref>
